U.S. Stem Cell, Inc. (USRM)

OTCMKTS: USRM · Delayed Price · USD
0.00 (0.00%)
May 15, 2024, 10:53 AM EDT - Market open
Market Cap 642.00
Revenue (ttm) 19,974
Net Income (ttm) -567,311
Shares Out 641.51M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 450
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta -31.99
Analysts n/a
Price Target n/a
Earnings Date n/a

About USRM

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-der... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 15, 2008
Country United States
Stock Exchange OTCMKTS
Ticker Symbol USRM
Full Company Profile

Financial Performance

In 2022, U.S. Stem Cell's revenue was $82,049, a decrease of -59.13% compared to the previous year's $200,749. Losses were -$3.31 million, -22.91% less than in 2021.

Financial Statements


Mark Borman Appointed Chairman of the Board of USRM

SUNRISE, FL / ACCESSWIRE / March 9, 2022 / U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutio...

2 years ago - Accesswire